Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 6/20 | 0.41 |
| ▸ | RAB9A | P51151 | 6/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 4/20 | 0.41 |
| ▸ | NCOA3 | Q9Y6Q9 | 2/20 | 0.41 |
| ▸ | OGA | O60502 | 2/20 | 0.38 |
| ▸ | ACACB | O00763 | 4/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.37 |
| ▸ | ACACA | Q13085 | 1/20 | 0.37 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23911194 | 0.84 | L3MBTL1 (0.36) | L3MBTL1NPC1RAB9AALOX12NCOA3 | |
| SCHEMBL13166681 | 0.79 | MET (0.36) | — | |
| SCHEMBL23911263 | 0.77 | L3MBTL1 (0.33) | L3MBTL1ACACBACACA | |
| SCHEMBL10288661 | 0.73 | USP7 (0.42) | NPC1RAB9APOLB | |
| SCHEMBL23911060 | 0.72 | KDM5B (0.36) | NPC1RAB9A | |
| SCHEMBL23911550 | 0.72 | KDM5B (0.36) | NPC1RAB9A | |
| SCHEMBL23911061 | 0.72 | KDM5B (0.36) | NPC1RAB9A | |
| SCHEMBL23911242 | 0.72 | USP7 (0.47) | L3MBTL1NPC1RAB9AOGAPOLB | |
| SCHEMBL7668542 | 0.72 | POLB (0.45) | NPC1RAB9APOLB | |
| SCHEMBL6302247 | 0.72 | ALDH1A1 (0.53) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317134-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | RAPT THERAPEUTICS INC (US) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317134-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | USP7, SENP7, USP8 | L3MBTL1 849/4885NPC1 2576/4885RAB9A 2140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.